NEW YORK (GenomeWeb News) – Tethys Bioscience today announced that it and the Duke Clinical Research Institute have established the Prevail patient registry to analyze primary care ambulatory practices for risk factor management of patients in the US who have a high risk of converting to type 2 diabetes.
Data from Prevail — a multicenter, national initiative — will better inform the challenges of diabetes prevention, Tethys said. Using the data, physicians, quality improvement personnel healthcare administrators, and others may be able to "optimize practice algorithms" and create educational interventions specifically targeting high-risk patients to improve therapeutic outcomes and reduce the incidence of type 2 diabetes and cardiovascular diseases associated with diabetes.
"We believe that Prevail presents an opportunity to demonstrate the need for more specific identification of individuals who are at the highest risk of developing type 2 diabetes so that we can better focus resources on interventions to preempt the growing epidemic of diabetes and other cardiometabolic conditions," said Mickey Urdea, chairman and CEO of Tethys, in a statement.
Prevail will be implemented in two phases. In the first phase, currently underway and lasting three months, retrospective data is being collected from a select number of sites. In the second phase, the data will be used to evaluate education and quality improvement interventions.
Based in Emeryville, Calif., Tethys develops and commercializes biomarker-based blood tests for chronic conditions. The firm's PreDx Diabetes Risk Score — a multi-marker blood test that identifies patients who have a high risk of developing type 2 diabetes within five years, is performed exclusively at Tethys' CLIA-certified clinical lab.